Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
At UCB we are over 8,000 doers & innovators who are passionate about creating & shaping the future. So, if you are curious, bold, smart, inspired & ready to shape the future, this is the moment to join us. Find out more: https://t.co/wkfuD3M
— UCB News (@ucb_news) 22.06.2021 -
Today is ALS Awareness Day. In honor of the #ALS community, we’re spreading awareness of this progressive neurodegenerative disorder to support people living with ALS and stand by them in their fight against this disease. #ALSMNDWithoutBorders https://t.c
— UCB News (@ucb_news) 21.06.2021 -
UCB: Proud members of the global neurology community, committed to delivering transformational outcomes and experiences for people living with neurological diseases. #UCB #EANpartners #EAN2021 https://t.co/4HcAPIluvY
— UCB News (@ucb_news) 21.06.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
